Breast Cancer Drug Possibly Linked To Endometrial Cancer
This week the Lancet medical journal reported that tamoxifen, a drug that has been used for twenty years to treat breast cancer, poses risks of endometrial cancer or cancer of the womb for women who use it long-term. Yet, Dutch researchers who have observed more than 300 women on tamoxifen conclude "that the benefits of the drug for those who have suffered breast cancer still far outweigh the risks." Reports indicate that cancer survival rates were 77% for persons using tamoxifen for long-term use versus 94% among non-tamoxifen users.
Media Resources: The Guardian (http://www.guardian.co.uk) 08 September 2000